LCLucy Caselton

Lucy Caselton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucy Caselton has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First- in- human in- vivo depiction of paraganglioma metabolism by hyperpolarised 13C-magnetic resonance

    by Rafat Chowdhury, Myuri Moorthy, Lorna Smith, Christoph a Mueller, Fiona Gong, Harriet j Rogers, Marianthi-vasiliki Papoutsaki, Tom Syer, Giorgio Brembilla, Saurabh Singh, et al.

    Phaeochromocytomas (PCC) and paragangliomas (PGL), cumulatively referred to as PPGLs, are neuroendocrine tumours arising from neural crest- derived cells in the sympathetic and parasympathetic nervous systems. Predicting future tumour behaviour and the likelihood of metastatic disease remains problematic as genotype-phenotype correlations are limited, the disease has variable penetrance and, to date, no reliable molecular, cellular or histological markers have emerged. Tumour metabolism quantification can be considered as a method to delineating tumour aggressiveness by utilising hyperpolarised 13 C- MR (HP- MR). The technique may provide an opportunity to non- invasively characterise disease behaviour. Here, we present the first instance of the analysis of PPGL metabolism via HP- MR in a single case.

  • Open Access

    A reproducible dynamic phantom for sequence testing in hyperpolarised 13C-magnetic resonance

    by Rafat Chowdhury, Marianthi-Vasiliki Papoutsaki, Christoph A Müller, Lorna Smith, Fiona Gong, Max Bullock, Harriet Rogers, Manju Mathew, Tom Syer, Saurabh Singh, et al.

    Objective: To develop a phantom system which can be integrated with an automated injection system, eliminating the experimental variability that arises with manual injection; for the purposes of pulse sequence testing and metric derivation in hyperpolarised 13C-MR. Methods: The custom dynamic phantom was machined from Ultem and filled with a nicotinamide adenine dinucleotide and lactate dehydrogenase mixture dissolved in phosphate buffered saline. Hyperpolarised [1-13C]-pyruvate was then injected into the phantom (n = 8) via an automated syringe pump and the conversion of pyruvate to lactate monitored through a 13C imaging sequence. Results: The phantom showed low coefficient of variation for the lactate to pyruvate peak signal heights (11.6%) and dynamic area-under curve ratios (11.0%). The variance for the lactate dehydrogenase enzyme rate constant (kP) was also seen to be low at 15.6%. Conclusion: The dynamic phantom demonstrates high reproducibility for quantification of 13C-hyperpolarised MR-derived metrics. Establishing such a phantom is needed to facilitate development of hyperpolarsed 13C-MR pulse sequenced; and moreover, to enable multisite hyperpolarised 13C-MR clinical trials where assessment of metric variability across sites is critical. Advances in knowledge: The dynamic phantom developed during the course of this study will be a useful tool in testing new pulse sequences and standardisation in future hyperpolarised work.